Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.440
-0.030 (-1.21%)
At close: Mar 13, 2026, 4:00 PM EDT
2.519
+0.079 (3.22%)
After-hours: Mar 13, 2026, 7:59 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 294 employees as of December 31, 2025. The number of employees decreased by 10 or -3.29% compared to the previous year.
Employees
294
Change (1Y)
-10
Growth (1Y)
-3.29%
Revenue / Employee
$1,371,207
Profits / Employee
-$77,150
Market Cap
626.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 294 | -10 | -3.29% |
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,788 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Emergent BioSolutions | 900 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Kamada | 420 |
| Aquestive Therapeutics | 147 |
ESPR News
- 3 days ago - Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 days ago - Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript - Seeking Alpha
- 10 days ago - Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Business Wire
- 23 days ago - Esperion to Participate in The 2026 Citizens Life Sciences Conference - GlobeNewsWire
- 24 days ago - Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 - GlobeNewsWire
- 4 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha